Geode Capital Management LLC raised its position in Doximity, Inc. (NASDAQ:DOCS - Free Report) by 19.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,856,984 shares of the company's stock after buying an additional 472,565 shares during the quarter. Geode Capital Management LLC owned about 1.54% of Doximity worth $124,503,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in DOCS. M&T Bank Corp bought a new position in Doximity in the third quarter valued at approximately $351,000. Barclays PLC increased its stake in shares of Doximity by 60.5% in the 3rd quarter. Barclays PLC now owns 53,401 shares of the company's stock valued at $2,327,000 after purchasing an additional 20,125 shares during the last quarter. Orion Portfolio Solutions LLC bought a new position in shares of Doximity in the 3rd quarter valued at $260,000. State Street Corp raised its holdings in shares of Doximity by 2.5% during the 3rd quarter. State Street Corp now owns 3,693,982 shares of the company's stock worth $160,947,000 after buying an additional 88,922 shares in the last quarter. Finally, Morse Asset Management Inc bought a new stake in shares of Doximity during the 3rd quarter worth $46,000. 87.19% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ:DOCS opened at $52.71 on Wednesday. Doximity, Inc. has a fifty-two week low of $22.96 and a fifty-two week high of $61.75. The company has a 50 day simple moving average of $48.41 and a two-hundred day simple moving average of $38.36. The company has a market capitalization of $9.84 billion, a PE ratio of 60.58, a P/E/G ratio of 4.16 and a beta of 1.40.
A number of research firms have issued reports on DOCS. Canaccord Genuity Group cut Doximity from a "buy" rating to a "hold" rating and lifted their target price for the company from $40.00 to $60.00 in a research report on Wednesday, November 13th. JPMorgan Chase & Co. upped their price objective on shares of Doximity from $30.00 to $48.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. Morgan Stanley upgraded shares of Doximity from an "underweight" rating to an "equal weight" rating and raised their target price for the company from $33.00 to $53.00 in a research report on Thursday, November 14th. Raymond James reiterated an "outperform" rating and set a $65.00 price target (up from $37.00) on shares of Doximity in a report on Friday, November 8th. Finally, Evercore ISI raised their price objective on Doximity from $34.00 to $45.00 and gave the company an "in-line" rating in a report on Tuesday, October 8th. Twelve research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $52.44.
Read Our Latest Report on Doximity
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.